Palisade Bio Shares Drop Following Commencement Of Late-Stage Return Of Bowel Study

Palisade Bio PALI has dosed first patient in its Phase 3 study evaluating lead asset LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

The Phase 3 study is designed to evaluate the safety and efficacy of LB1148, and set to enroll approximately 600 patients.

The enrolled patients will undergo a scheduled bowel resection surgery that will include either laparotomy or minimally invasive surgical approaches.

The design of this Phase 3 study is similar to the positive Phase 2 study where LB1148 demonstrated a statistically significant improvement in the time of return of bowel function.

The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery, defined as the time from the end of surgery to the toleration of food and first bowel movement.

Tom Hallam, Chief Executive Officer, said, "The dosing of our first patient in the LB1148 Phase 3 marks a noteworthy milestone for the company and another important step forward in the execution of our strategy. With what we believe to be a pivotal Phase 3 study now fully underway, we are focused on building momentum and completing enrollment as quickly and efficiently as possible.”

Price Action : Palisade shares are trading around 13 percent down at $0.18 on Wednesday at the time of publication.

Posted In: BiotechPenny StocksHealth CareMovers & ShakersMarketsGeneralPatient Enrollment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...